\n
![\"NHS](\"https:\/\/stg-blogs.bmj.com\/bmj\/files\/2015\/03\/nhs_logo1.jpg\"){kind=logo}
<\/a>\u2022 In an analysis article, David Hunter argues that, rather than exclude politics from health<\/a>, we must embrace it if we are to improve our complex health systems.<\/p>\nPolitical science can, he urges, provide the insights needed to improve policy. \u201cIt has the potential to be of immense practical value in generating solutions to complex problems that have so far largely defeated policy makers and practitioners,\u201d he says.<\/p>\n
Patients and professionals<\/strong> \u201cWe need a revolution where patients truly come first, not politicians, because if professionals and patients are not on the same side we are sunk,\u201d she says.<\/p>\n Hip replacement revision rates<\/strong> They find that 10 year revision rate estimates were all less than 5%, and in some instances considerably less. \u201cThe results suggest that the current revision rate benchmark should be at least halved from 10% to less than 5% at 10 years,\u201d they say. \u201cThis has implications for benchmarks internationally.\u201d<\/p>\n Tom Moberly<\/strong> is the editor of BMJ Careers.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Here\u2019s your Tuesday roundup: Politics and health \u2022 In an analysis article, David Hunter argues that, rather than exclude politics from health, we must embrace it if we are to improve our complex health systems. Political science can, he urges, provide the insights needed to improve policy. \u201cIt has the potential to be of immense […]<\/p>\n
\n\u2022 Margaret McCartney says we need to overhaul the relationship<\/a> between patients and health professionals.<\/p>\n![\"research_key\"](\"https:\/\/stg-blogs.bmj.com\/bmj\/files\/2015\/03\/research_key-300x194.jpg\")
<\/a>Reports of stalled drug trials<\/strong>
\n\u2022 Amanda Hakala and colleagues have looked at the proportion of trials for unsuccessfully licensed drugs<\/a> that are not published. They find that much of the information collected in unsuccessful drug trials is inaccessible to the broader research and practice communities.<\/p>\n
\n![\"Hip_Prosthesis\"](\"https:\/\/stg-blogs.bmj.com\/bmj\/files\/2015\/03\/Hip_Prosthesis-300x194.jpg\")
<\/a>\u2022 Ngianga-Bakwin Kandala and colleagues have compared 10 year revision rates<\/a>\u00a0for primary total hip replacement to inform the setting of a new benchmark rate.<\/p>\n